Development Of Monoclonal Antibody Therapy For Treating Wounds
Funder
National Health and Medical Research Council
Funding Amount
$573,354.00
Summary
Chronic wounds, diabetic ulcers, injuries in response to trauma, burns and scalds form a medical need which will only expand as the population ages and the diabetic epidemic grows. In our studies, we have shown that Flightless I (Flii), an actin-remodelling protein, is a negative regulator of wound healing. We are developing monoclonal antibodies as a new therapy for reducing Flii levels in wounds which leads to improved wound repair outcomes.
Wounds and burn injuries are frequent injuries which can lead to deformity, disfigurement and loss of movement. The cytoskeleton is integral to the wound healing process and we have shown that a specific cytoskeletal protein, Flightless I (Flii), is an important regulator of wound repair. During the course of this fellowship I plan to further my investigations into the function and regulation of Flii in wounds and aim to develop new therapies for treating wounds and reducing scar formation.